Immunology of systemic sclerosis

Frontiers in Bioscience

Volumn 10, Issue 2, 2005, Pages 1707-1719

  Artlett, Carol M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Autoantibodies; Environmental Agents; Microchimerism; Pathogenesis; Review; Scleroderma; Systemic Sclerosis; T cells

Indexed keywords

AUTOANTIBODY; DNA DIRECTED RNA POLYMERASE; FIBRILLARIN; RNA POLYMERASE II; SCL 70 ANTIBODY;

ARTICLE; BLOOD; CELLULAR IMMUNITY; CHIMERA; CYTOMEGALOVIRUS; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENETIC ANALYSIS; HISTORY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENETICS; NONHUMAN; PARVOVIRUS; PATHOGENESIS; STATISTICAL ANALYSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

CYTOMEGALOVIRUS; PARVOVIRUS; SCLERODERMA;

EID: 17244364387     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1654     Document Type: Article

References (151)

1. Rodnan, G. P. and T. G. Benedek. An historical account of the study of progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 57:305-319 (1962)
2. Curzio, C. Discussioni anatomico-pratiche di un raro, e stravagante morbo cutaneo in una giovane Donna felicemente curato in questo grande Ospedale degl' Incurabili, Giovanni di Simone, Naploi. Anatomico-Pratiche (1753)
3. Matsui, S. Uber die pathologie und pathogenese von skleroderma universalis. Mitt Med Fakult Kaiserl Univ Tokyo 31:55-60 (1924)
4. Goetz, R. H. Pathology of progressive systemic sclerosis (generalized scleroderma) with special reference to changes in the viscera. Clin Proc (S Afr) 4:337-339 (1945)
5. Jimenez, S. A. and C. T. Derk. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140:37-50 (2004)
6. Arnett, F. C., R. F. Howard, F. Tan, J. M. Moulds, W. B. Bias, E. Durban, H. D. Cameron, G. Paxton, T. Hodge, P. E. Weathers, and J. D. Reveille. Increased prevalence of systemic sclerosis in a native American tribe in Oklahoma. Arthritis Rheum 39:1362-1370 (1996)
7. Le Guern, V., A. Mahr, L. Mouthon, D. Jeanneret, M. Carzon, and L. Guillevin. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology 43:1129-1137 (2004)
8. Giordano, M., G. Valentini, M. Ara, G. Tirri, L. Capelli, and M. Vatti. Epidemiology of progressive systemic sclerosis in Italy. In Current Topics in Rheumatology. Systemic sclerosis (scleroderma). C. M. Black and A. R. Myers, eds. Gower Publisher, New York, pp. 72-77 (1985)
9. Asboe-Hansen, G. 1985. Epidemiology of progressive systemic sclerosis in Denmark. In Current topics in Rheumatology. Systemic sclerosis (scleroderma). C. M. Black and A. R. Myers, eds. Gower Publishing, New York, p. 78 (1985)
10. Allcock, R. J., I. Forrest, P. A. Corris, P. R. Crook, and I. D. Griffiths. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 43:596-602 (2004)
11. Shinkai, H. 1985. Epidemiology of progressive systemic sclerosis in Japan. In Current topics in Rheumatology. Systemic sclerosis (scleroderma). C. M. Black and A. R. Myers, eds. Gower Publishing, New York, pp. 79-81 (1985)
12. Roberts-Thomson, P. J., M. Jones, P. Hakendorf, A. A. S. S. K. Dharmapatni, J. G. Walker, J. G. Macfarlane, M. D. Smith, and M. J. Ahern. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Internal Med J 31:220-229 (2001)
13. Silman, A. J., Y. Howard, A. J. Hicklin, and C. M. Black. Geographical clustering of scleroderma in south and west London. Br J Rheumatol 29:92-96 (1990)
14. Thompson, A. E. and J. E. Pope. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 29:1867-1873 (2002)
15. Haustein, U.-F. and K. Herrmann. Environmental scleroderma. Clin Dermatol 12:467-473 (1994)
16. Haustein, U.-F., V. Ziegler, and K. Herrmann. Chemically-induced scleroderma. Hautarzt 43:469-474 (1996)
17. Silman, A. J. and M. C. Hochberg. Occupational and environmental influences on scleroderma. Rheum Dis Clin NA 22:737-749 (1996)
18. Haustein, U.-F., V. Ziegler, E. Zschunke, H. Munzberger, and H. Kopping. Progressive systemic sclerosis with silicosis in the German Democratic Republic. In Current topics in Rheumatology. Systemic sclerosis (scleroderma). C. M. Black and A. R. Myers, eds. Gower Publishing, New York, pp. 138-141 (1985)
19. Maricq, H. R. Vinyl chloride disease. In Current topics in Rheumatology. Systemic sclerosis (scleroderma). C. M. Black and A. R. Myers, eds. Gower Publishing, New York, pp. 105-113 (1985)
20. Ward, A. M., S. Udnoon, J. Watkins, A. E. Walker, and C. C. Darke. Immunological mechanism in the pathogenesis of vinyl chloride disease. Br Medical J 1:936-938 (1976)
21. Mayes, M. D. Scleroderma epidemiology. Rheum Dis Clin NA 22:751-764 (1996)
22. Silman, A. J., S. Jannini, D. Symmons, and P. Bacon. An epidemiologic study of scleroderma in the West Midlands. Br J Rheumatol 27:286-290 (1988)
23. Black, C. M. and K. I. Welsh. Genetics of scleroderma. Clin Dermatol 12:337-347 (1994)
24. Artlett, C. M., Otieno, F. G., Cane, J. R., Lopez, A. M., and Jimenez, S. A. Allograft inflammatory factor-1 gene polymorphisms and tissue expression in systemic sclerosis. Arthritis Rheum 50 (Suppl): S440 (2004)
25. Black, C. M., K. I. Welsh, A. E. Walker, R. M. Bernstein, L. J. Catoggio, A. R. McGregor, and J. K. Lloyd Jones. Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride. Lancet 1:53-55 (1983)
26. Fanning, G. C., K. I. Welsh, C. Bunn, R. Du Bois, and C. M. Black. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 37:201-207 (1998)
27. Sato, H., A. L. Lagan, C. Alexopoulou, D. A. Vassilakia, T. Ahmad, P. Pantelidis, S. Veeraraghavan, E. Renzoni, C. Denton, C. Black, A. U. Wells, R. M. Du Bois, and K. I. Welsh. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 50:558-564 (2004)
28. Jimenez, S. A., A. Diaz, and K. Khalili. Retroviruses and the pathogenesis of systemic sclerosis. Int Rev Immunol 12:159-17 (1995)
29. Pandey, J. P. and E. C. LeRoy. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 41:10-15 (1998)
30. Magro, C. M., G. Nuovo, C. Ferri, A. N. Crowson, D. Giuggioli, and M. Sebastiani. Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma. J Cutan Pathol 31:43-50 (2004)
31. gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci USA 86:8492-8496 (1989)
32. Priel, E., S. D. Showalter, M. Roberts, S. Oroszlan, S. Segal, M. Aboud, and D. G. Blair. Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core. EMBO J 9:4167-4172 (1990)
33. Regner, M. and P. H. Lambert. Autoimmunity through infection or immunization? Nature Immunology 2:185-188 (2001)
34. Miller, S. D., C. L. Vanderlugt, W. S. Begolka, W. Pao, R. L. Yauch, K. L. Neville, Y. Katz-Levy, A. Carrizosa, and B. S. Kim. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nature Medicine 3:1133-1136 (1997)
35. Andersen, O., P. E. Lygner, T. Bergstrom, M. Andersson, and A. Vahlne. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 240:417-422 (1993)
36. Oldstone, M. B. A. Molecular mimicry and autoimmune disease. Cell 50:819-820 (1987)
37. Wucherpfennig, K. W. and J. L. Strominger. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705 (1995)
38. Hiemstra, H. S., N. C. Schloot, P. A. van Veelen, S. J. Willemen, K. L. M. C. Franken, J. J. van Rood, R. P. P. de Vries, A. Chaudhuri, P. O. Behan, and J. W. Drijfhout. Cytomegalovirus in autoimmunity: T cell cross-reactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci USA 98:3988-3991 (2001)
39. Oomes, P. G., B. C. Jacobs, M. P. Hazenberg, J. R. Banffer, and F. G. van der Meche. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillian-Barre syndrome: evidence for molecular mimicry. Ann Neurol 38:170-175 (1995)
40. Weiner, E. S., W. C. Earnshaw, J.-L. Senecal, B. Bordwell, P. Johnson, and N. F. Rothfield. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 31:378-385 (1988)
41. Kuwana, M., J. Kaburaki, Y. Okano, H. Inoko, and K. Tsuji. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis. J Clin Invest 92:1296-1301 (1993)
42. Shuman, S. and B. Moss. Identification of a vaccinia virus gene encoding a type I DNA topoisomerase. Proc Natl Acad Sci USA 84:7478-7482 (1987)
43. Shaffer, R. and P. Traktman. Vaccinia virus encapsidates a novel topoisomerase with the properties of a eukaryotic type I enzyme. J Biol Chem 262:9309-9315 (1987)
44. Campbell, P. M. and E. C. LeRoy. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 4:351-368 (1975)
45. Lunardi, C., C. Bason, R. Navone, E. Millo, G. Damonte, R. Corrocher, and A. Puccetti. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nature Medicine 6:1183-1186 (2000)
46. Neidhart, M., S. Kuchen, O. Distler, P. Bruhlmann, B. A. Michel, R. E. Gay, and S. Gay. Increased serum levels of antibodies against human cytomegalovirus and prevalentce of autoantibodies in systemic sclerosis. Arthritis Rheum 42:389-392 (1999)
47. Altschuler, E. L. The historical record is consistent with the recent finding of parvovirus B19 infection of the bone marrow in systemic sclerosis. Clin Exp Rheumatol 19:228 (2001)
48. Kerr, J. R., M. McCoy, B. Burke, D. L. Mattey, V. Pravica, and I. V. Hutchinson. Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. J Clin Pathol 56:725-727 (2003)
49. Ohtsuka, T., A. Yamakage, and S. Yamazaki. The polymorphism of growth factor-b1 gene in Japanese patients with systemic sclerosis. Br J Dermatol 147:458-463 (2002)
50. Ohtsuka, T. and S. Yamazaki. Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin. Br J Dermatol 150:1091-1095 (2004)
51. Abu-Shakra, M., S. Sukenik, and D. Buskila. Systemic sclerosis: another rheumatic disease associated with hepatitus C virus infection. Clin Rheumatol 19:378-380 (2000)
52. Longo, F., S. Saletta, L. Lepore, and M. Pennesi. Localized scleroderma after infection with Epstein-Barr virus. Clin Exp Rheumatol 11:681-683 (1993)
53. Douvas, A. and S. Sobelman. Mulitple overlapping homologies between two rheumatoid antigens and immunosuppressive viruses. Proc Natl Acad Sci USA 88:6328-6332 (1991)
54. Lawley, T. J., G. L. Peck, H. M. Moutsopoulos, A. A. Gratwohl, and A. B. Deisseroth. Scleroderma, Sjögren-like syndrome and chronic graft-versus-host disease. Ann Intern Med 87:707-709 (1977)
55. Graham-Brown, R. A. C. and I. Sarkani. Scleroderma-like changes due to chronic-graft-versus host disease. Clin Exp Dermatol 8:531-538(1983)
56. Herzog, P., P. J. Clements, N. K. Roberts, D. E. Furst, C. E. Johnson, and S. A. Feig. Progressive systemic sclerosis-like syndrome after bone marrow transplantation. J Rheumatol 7:56-64 (1980)
57. Valenta, L. J. Familial scleroderma in a kindred with high incidence of autoimmune disease: correlation with HLA-A1/B8 haplotype. Arch Dermatol 123:1438-1440 (1987)
58. Bos, G. M. J., G. D. Majoor, D. W. Slaaf, M.-J. W. H. Van der Gaar, J. S. Weijmer-van Velzen, and P. J. C. van Breda Vriesman. Similarity of scleroderma-like skin lesions in allogeneic and syngeneic bone marrow transplantation models. Transplant Proc 21:3262-3263 (1989)
59. Black, C. M. and W. M. Stevens. Scleroderma. Rheum Dis Clin NA 15:193-212 (1989)
60. Chosidow, O., M. Bagot, J.-P. Vernant, J.-C. Roujeau, C. Cordonnier, M. Kuentz, J. Wechsler, C. Andre, R. Touraine, and J. Revuz. Sclerodermatous chronic graft-versus-host disease. J Am Acad Dermatol 26:49-55 (1992)
61. Nelson, J. L. Maternal-fetal immunology and autoimmune disease: Is some autoimmune disease auto-alloimmune or allo-autoimmune? Arthritis Rheum 39:191-194 (1996)
62. Artlett, C. M., K. I. Welsh, C. M. Black, and S. A. Jimenez. Fetal-maternal HLA compatibility confers susceptibility to systemic sclerosis. Immunogenet 47:17-22 (1997)
63. Artlett, C. M., J. B. Smith, and S. A. Jimenez. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Eng J Med 338:1186-1191 (1998)
64. Nelson, J. L., D. E. Furst, S. Maloney, T. Gooley, D. C. Evans, A. Smith, M. A. Bean, C. Ober, and D. W. Bianchi. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 351:559-562 (1998)
65. Silman, A. J. and C. M. Black. Increased incidence of spontaneous abortion and infertility with scleroderma before disease onset: a controlled study. Ann Rheum Dis 47:441-444 (1988)
66. Fleischmajer, R., J. S. Perlish, and J. R. T. Reeves. Cellular infiltrates in scleroderma skin. Arthritis Rheum 20:975-984 (1977)
67. Lambert, I. A., A. J. Switters, and G. Janossy. Lymphoid infiltrates in skin in graft-versus-host disease. Lancet 2:1352 (1981)
68. Jimenez, S. A. Cellular immune dysfunction and the pathogenesis of scleroderma. Semin Arthritis Rheum 13 (Suppl. 1):104-113 (1983)
69. Kahaleh, M. B. and E. C. LeRoy. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med 110:446-450 (1989)
70. Fagundus, D. M. and E. C. LeRoy. Cytokines and systemic sclerosis. Clin Dermatol 12:407-417 (1994)
71. Postlethwaite, A. E. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol 5:766-772 (1993)
72. Janin-Mercier, A., A. Devergie, D. van Cauwenberge, M. Bourges, Ch. M. Lapiere, and E. Guckman. Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man. Am J Pathol 115:296-306 (1984)
73. Jimenez, S. A., E. Hitraya, and J. Varga. Pathogenesis of scleroderma: collagen. Rheum Dis Clin NA 22:647-674 (1996)
74. White, B., J. H. Korn, and T. H. Piela-Smith. Preferential adherence of human gamma delta, CD8+, and memory T cells to fibroblasts. J Immunol 152:4912-4918 (1994)
75. LeRoy, E. C., C. M. Black, R. Fleischmajer, S. Jablonska, T. Krieg, T. A. Medsger, N. Rowell, and F. Wollheim. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205 (1988)
76. Bell, S. A., H. Faust, J. Mittermuller, H.-J. Kolb, and M. Meurer. Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol 134:848-854 (1996)
77. Siegert, W., R. Stemerowicz, and U. Hopf. Antimitochondrial antibodies in patients with chronic graft-versus-host disease. Bone Marrow Transplant 10:221-227 (1992)
78. Mullinax, F. Chimerism in scleroderma. Lancet 351:1886 (1998)
79. Bianchi, D. W., G. K. Zickwolf, G. J. Weil, S. Sylvester, and M. A. Demaria. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci USA 93:705-708 (1996)
80. Artlett, C. M., Sawaya, H. H. B., Johnson-Hopson, C. N., Ramos, R. C., Jimenez, S. A., and Smith, J. B. Microchimeric cells identified by immunophenotyping and fluorescence in situ hybridization in active lesions from patients with systemic sclerosis are activated T cells. Arthritis Rheum. 46(Suppl), S458. (2002)
81. Dzik, W. H. Microchimerism after transfusion: the spectrum from GVHD to alloimmunization. Transfus Sci 16:107-108 (1995)
82. Otori, K., C. Masuda, H. Wanibuchi, A. Nakanishi, K. Kawabata, H. Ohashi, and S. Fukushima. An autopsy report of graft-versus-host disease (GVHD) following blood transfusion. Osaka City Med 45:37-43 (1999)
83. Scaletti, C., A. Vultaggio, S. Bonifacio, L. Emmi, F. Torricelli, E. Maggi, S. Romagnani, and M. P. Piccinni. TH2-Oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum 46:445-450 (2002)
84. Artlett, C. M., M. Rasheed, K. E. Russo-Stieglitz, H. H. B. Sawaya, and S. A. Jimenez. Influence of prior pregnancies on disease course and cause of death in systemic sclerosis. Ann Rheum Dis 61:346-350 (2002)
85. Ruzek, M. C., S. Jha, S. Ledberter, S. M. Richards, and R. D. Garman. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 50:1319-1331 (2004)
86. Harvey, G. R. and N. J. McHugh. Serologic abnormalities in systemic sclerosis. Curr Opin Rheumatol 11:495-502 (1999)
87. Steen, V. D., G. L. Ziegler, G. P. Rodnan, and T. A. Medsger. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27:125-131 (1984)
88. Fritzler, M. J. and T. D. Kinsella. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520-526 (1980)
89. McCarty, G. A., J. R. Rice, M. L. Bembe, and F. A. Barada. Anticentromere antibody. Clinical correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum 26:1-7 (1983)
90. Genth, E., R. Mierau, P. Genetzky, C. von Muhlen, S. Kaufmann, H. von Wilmowsky, M. Meurer, T. Krieg, H.-J. Pollman, and P. W. Hartl. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 33:657-665 (1990)
91. Reveille, J. D., E. Durban, M. J. MacCleod-St.Clair, R. Goldstein, R. Moreda, R. D. Altman, and F. C. Arnett. Association of amino acid sequences in the HLA-DQB1 first domain with the antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 90:1-8 (1992)
92. Whyte, J., C. M. Artlett, G. Harvey, C. O. Stephens, K. I. Welsh, C. M. Black, P. J. Maddison, and N. J. McHugh. HLA-DQB1 associations with anti-topoisomerase-1 antibodies in patients with systemic sclerosis and their first degree relatives. United Kingdom Systemic Sclerosis Group. J Autoimmun 7:509-520 (1994)
93. Douvas, A. Pathogenesis: serologic correlates. In Systemic Sclerosis. P. J. Clements and D. E. Furst, eds. Williams & Wilkins, Baltimore, pp. 175-202 (1996)
94. Reveille, J. D., E. Durban, R. Goldstein, R. Moreda, and F. C. Arnett. Racial differences in the frequencies of sclerodermarelated autoantibodies. Arthritis Rheum 35:216-218 (1992)
95. Kuwana, M., Y. Okano, J. Kaburaki, T. Tojo, and T. A. Medsger. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 37:902-906 (1994)
96. Rothfield, N., D. Whitaker, B. Bordwell, E. Weiner, J.-L. Senecal, and W. Earnshaw. Detection of anticentromere antibodies using cloned autoantigen CENP-B. Arthritis Rheum 30:1416-1419 (1987)
97. Powell, F. C., R. K. Winkelmann, F. Venencie-Lemarchand, J. L. Spurbeck, and A. L. Schroeter. The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 59:700-706 (1984)
98. Reimer, G., V. D. Steen, C. A. Penning, T. A. Medsger, and E. M. Tan. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 31:525-532 (1988)
99. Kuwana, M., J. Kaburaki, Y. Okano, T. Tojo, and M. Homa Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75-83 (1994)
100. Chang, M., R. J. Wang, D. T. Yangco, G. C. Sharp, G. R. Komatireddy, and R. W. Hoffman. Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 89:71-78 (1998)
101. Okano, Y., V. D. Steen, and T. A. Medsger. Antibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005-1013 (1993)
102. Stetler, D. A., K. M. Rose, M. E. Wenger, C. M. Berlin, and S. T. Jacob. 1982. Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease. Proc Natl Acad Sci USA 79:7499-7503 (1982)
103. Okano, Y., V. D. Steen, and T. A. Medsger. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95-100 (1992)
104. Sacks, D. G., Y. Okano, V. D. Steen, E. Curtiss, L. S. Shapiro, and T. A. Medsger. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 23:639-642 (1996)
105. Kasturi, K. N., A. Hatakeyama, H. Spiera, and C. A. Bona. Antifibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes. J Exp Med 181:1027-1036 (1995)
106. Mouritsen, S., E. Demant, H. Permin, and A. Wiik. High prevalence of anti-mitochondrial antibodies among patients with some well-defined connective tissue diseases. Clin Exp Immuno. 66:68-76 (1986)
107. Isern, R. A., M. Yaneva, E. Weiner, A. Parke, N. Rothfield, D. Dantzker, S. Rich, and F. C. Arnett. Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am J Med 93:307-312 (1992)
108. Briggs, D. C., C. M. Black, and K. I. Welsh. Genetic factors in scleroderma. Rheum Dis Clin NA 16:31-51 (1990)
109. Kuwana, M., J. Kaburaki, F. C. Arnett, R. F. Howard, T. A. Medsger, and T. M. Wright. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 42:465-474 (1999)
110. McHugh, N. J., J. Whyte, C. M. Artlett, D. C. Briggs, C. O. Stephens, N. Olsen, N. G. Gusseva, P. J. Maddison, C. M. Black, and K. I. Welsh. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study. Clin Exp Immunol 96:267-274 (1994)
111. Rands, A. L., J. Whyte, B. Cox, N. D. Hall, and N. J. McHugh. MHC class II associations with autoantibody and T cell immune responses to the scleroderma autoantigen topoisomerase I. J Autoimmun 15:451-458 (2000)
112. Gilchrist, F. C., C. Bunn, P. J. Foley, P. A. Lympany, C. M. Black, K. I. Welsh, and R. M. Du Bois. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immunity 2:76-81 (2001)
113. Whiteside, T. L., T. A. Medsger, and G. P. Rodnan. HLA-DR antigens in progressive systemic sclerosis (scleroderma). J Rheumatol 10:128-131 (1983)
114. Reveille, J. D., D. Owerbach, R. Goldstein, R. Moreda, R. A. Isern, and F. C. Arnett. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with anticentromere antibody response in systemic sclerosis (scleroderma). J Clin Invest 89:1208-1213 (1992)
115. Briggs, D. C., K. Welsh, R. S. Pereira, and C. M. Black. A strong association between null alleles at the C4A locus in the major histocompatibility complex and systemic sclerosis. Arthritis Rheum 29:1274-1277 (1986)
116. Rittner, G., G. Schwanitz, M. P. Baur, C. M. Black, K. I. Welsh, P. Kuhnl, and C. Rittner. Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes. Hum Genet 81:64-70 (1988)
117. Laurent, M. R. and K. I. Welsh. Genetic markers in rheumatological diseases. J Immunogenet 10:275-291 (1983)
118. Medsger, T. A., S. Bombardieri, L. Czirjak, R. Scorza, A. Della Rossa, and W. Bencivelli. Assessment of disease severity and prognosis. Clin Exp Rheumatol 21:S42-S46 (2003)
119. Keystone, E. C., C. Lau, D. Gladman, S. Wilkinson, P. Lee, and A. Shore. Immunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies. Clin Exp Immunol 48:443-448 (1982)
120. Lupoli, S., P. Amlot, and C. Black. Normal immune responses in systemic sclerosis. J Rheumatol 17:323-327 (1990)
121. Kraling, B. M., S. A. Jimenez, T. Sorger, and G. G. Maul. Isolation and characterization of microvascular endothelial cells from the adult dermis and from skin biopsies of patients with systemic sclerosis. Lab Invest 71:745-754 (2002)
122. Prescott, R. J., A. J. Freemont, C. J. Jones, J. Hoyland, and P. Fielding. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255-263 (1992)
123. Roumm, A. D., T. L. Whiteside, T. A. Medsger, and G. P. Rodnan. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27:645-653 (1984)
124. Kahari, V., M. Sandberg, H. Kalimo, T. Vuorio, and E. Vuorio. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 90:664-670 (1988)
125. Peltonen, J., L. Kahari, J. Uitto, and S. A. Jimenez. Increased expression of Type VI collagen genes in systemic sclerosis. Arthritis Rheum 33:1829-1835 (1990)
126. Rudnicka, L., J. Varga, A. M. Christiane, R. V. Iozzo, S. A. Jimenez, and J. Uitto. Elevated expression of type VI collagen in the skin of patients with systemic sclerosis. Regulation by transforming growth factor beta. J Clin Invest 93:1709-1715 (1994)
127. Jimenez, S. A., G. Feldman, R. I. Bashey, R. Bienkowski, and J. Rosenbloom. Co-ordinate increase in expression of Type I and Type III collagen genes in progressive systemic sclerosis fibroblasts. Biochem J 237:837-843 (1986)
128. Kuroda, K. and H. Shinkai. Decorin and glycosaminoglycan synthesis in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 289:481-485 (2001)
129. Cooper, S. M., A. J. Keyser, A. D. Beaulieu, E. Ruoslahti, M. E. Nimni, and F. P. Quismorio. Increase in fibronectin in the deep dermis of involved skin in progressive systemic sclerosis. Arthritis Rheum 22:983-987 (1979)
130. Rossi, G. A., P. B. Bitterman, S. I. Rennard, V. J. Ferrans, and R. G. Crystal. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis 131:612-617 (1985)
131. Wells, A. U., S. Lorimer, S. Majumdar, N. K. Harrison, B. Corrin, C. M. Black, P. K. Jeffery, and R. M. Du Bois. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in the interstitium. Eur Respir J 8:266-271 (2001)
132. Smith, E. A. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol 4:869-877 (1992)
133. Silver, R. M., K. S. Miller, M. B. Kinsella, E. A. Smith, and S. I. Schabel. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 88:470-476 (1990)
134. Gustafsson, R., K. Fredens, O. Nettelbladt, and R. Hallgren. Eosinophil activation in systemic sclerosis. Arthritis Rheum 34:414-422 (1991)
135. Yurovsky, V. V., F. M. Wigley, R. A. Wise, and B. White. Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 48:84-97 (1996)
136. White, B. and V. V. Yurovsky. Oligoclonal expansion of V delta 1+ gamma/delta T cells in systemic sclerosis patients. Ann NY Acad Sci 756:382-391 (1995)
137. Yurovsky, V. V., P. A. Sutton, D. H. Schulze, F. M. Wigley, R. A. Wise, R. F. Howard and B. White. Expansion of selected V delta 1+ gamma delta T cells in systemic sclerosis patients. J Immunol 153, 881-891 (1994)
138. Giacomelli, R., M. Matucci-Cerinic, P. Cipriani, I. Ghersetich, R. Lattanzio, A. Pavan, A. Pignone, M. L. Cagnoni, T. Lotti, and G. Tonietti. Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 41:327-334 (1998)
139. Sakkas, L. I., B. Xu, C. M. Artlett, S. A. Jimenez, and C. D. Platsoucas. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J.Immunol 168:3649-3659 (2002)
140. Majewski, S., M. Blaszczyk, M. Wasik, and S. Jablonska. Natural killer cell activity of peripheral blood mononuclear cells from patients with various forms of systemic scleroderma. Br J Dermatol 116:1-8 (1987)
141. Kantor, T. V., T. L. Whiteside, D. Friberg, R. B. Buckingham, and T. A. Medsger. Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis. Arthritis Rheum 35:694-699 (1992)
142. Whiteside, T. L., Y. Kumagai, A. D. Roumm, R. Almendinger, and G. P. Rodnan. Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. Arthritis Rheum 26:841-847 (1983)
143. Giacomelli, R., R. Cipriani, R. Lattanzio, M. Di Franco, M. Locanto, I. Parzanese, A. Passacantando, A. Ciocci, and G. Tonietti. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 108:42-46 (1997)
144. Mavilia, C., C. Scaletti, P. Romagnani, A. M. Carossino, A. Pignone, L. Emmi, C. Pupilli, G. Pizzolo, E. Maggi, and S. Romagnani. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751-1758 (1997)
145. Distler, J. H., C. Hagen, A. Hirth, U. Muller-Ladner, H. M. Lorenz, A. Del Rosso, B. A. Michel, R. E. Gay, R. Nanagara, K. Nishioka, M. Matucci-Cerinic, J. R. Kalden, S. Gay, and O. Distler. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor kappaB and simian virus 40 promoter factor 1 pathways. Mol Pharmacol 65:389-399 (2004)
146. Kikuchi, K., M. Kubo, T. Kadono, N. Yazawa, H. Ihn, and K. Tamaki. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 139:1049-1051 (1998)
147. Torres, J. E. and J. L. Sanchez. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol 20:242-245 (1998)
148. White Needleman, B., J. V. Ordonez, D. Taramelli, W. Alms, K. Gayer, and J. Choi. In vitro identification of a subpopulation of fibroblasts that produces high levels of collagen in scleroderma patients. Arthritis Rheum 33:842-852 (1990)
149. Ihn, H., S. Sato, M. Fukimoto, K. Kikuchi, T. Kadono, K. Tamaki, and K. Takehara. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 36:1270-1275 (1997)
150. Cho, M. M., S. A. Jimenez, B. A. Johnson, L. A. Harlow, J. C. Burrows, and A. E. Koch. In vitro cytokine modulation of intercellular adhesion molecule-1 expression on systemic sclerosis dermal fibroblasts. Pathobiology 62:73-81 (1994)
151. Gruschwitz, M. S. and G. Vieth. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule I expression on scleroderma fibroblasts and endothelial cells by interferon-g and tumor necrosis factor a in the early disease stage. Arthritis Rheum 40:540-550 (1997)